Who Paid My Doc
Adlyxin
Biological Endocrine & Metabolic Diseases
NDC 0024-5745-02
General payments
$17,236
Research payments
$2,363,116
Through program year 2025, $17,236 in general payments and $2,363,116 in research payments were reported against Adlyxin (Endocrine & Metabolic Diseases).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,250 | 1 |
| 2025 | Research | $3,750 | 3 |
| 2024 | General | $2,000 | 5 |
| 2024 | Research | $38,249 | 17 |
| 2023 | General | $10,419 | 3 |
| 2023 | Research | $1,563,810 | 204 |
| 2022 | General | $22 | 1 |
| 2022 | Research | $735,720 | 81 |
| 2021 | General | $3,545 | 3 |
| 2021 | Research | $21,587 | 32 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
13 general · 337 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.